These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19925426)

  • 1. Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development.
    Akkari PA; Swanson TW; Crenshaw DG; Grossman I; Sundseth S; Burns DK; Roses AD
    Curr Pharm Des; 2009; 15(32):3754-63. PubMed ID: 19925426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution of data of efficacy trials to judge the improvement of the medical usefulness of a drug].
    Bouvenot G; Eschwège E
    Therapie; 1992; 47(1):17-9. PubMed ID: 1523589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
    Gibson N; Jawaid A; March R
    Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic application in drug development and clinical trials.
    Shi MM; Bleavins MR; de la Iglesia FA
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):591-5. PubMed ID: 11259358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report on the joint EFPIA, DIA and EMEA pharmacogenetics workshop: moving toward clinical application.
    McCarthy A; Kerr M; Abadie E; Chibout SD; Imbert G; Cohen N; Drakoulis N; Knudsen LE; Flamion B; Hashimoto L; Kreutz WV; McHale D; Mitchell T; Papaluca Amati M; Roberts R; Shaw P; Stuerzebecher CS; Townend D
    Pharmacogenomics; 2004 Sep; 5(6):731-9. PubMed ID: 15335293
    [No Abstract]   [Full Text] [Related]  

  • 7. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches to drug safety: a pharmacovigilance tool kit.
    Wise L; Parkinson J; Raine J; Breckenridge A
    Nat Rev Drug Discov; 2009 Oct; 8(10):779-82. PubMed ID: 19763106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CuraGen Corporation.
    Mansfield T; Vincent MR
    Pharmacogenomics; 2002 Jul; 3(4):551-4. PubMed ID: 12164777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics and drug metabolism.
    Ball S; Borman N
    Nat Biotechnol; 1997 Oct; 15(10):925-6. PubMed ID: 9335033
    [No Abstract]   [Full Text] [Related]  

  • 13. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
    Ross JS; Ginsburg GS
    Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in drug development.
    McCarthy AD; Kennedy JL; Middleton LT
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1579-88. PubMed ID: 16096107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brave new pharmacy.
    Lemonick MD
    Time; 2001 Jan; 157(2):58-66, 69. PubMed ID: 11195690
    [No Abstract]   [Full Text] [Related]  

  • 16. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making.
    Trepicchio WL; Essayan D; Hall ST; Schechter G; Tezak Z; Wang SJ; Weinreich D; Simon R
    Pharmacogenomics J; 2006; 6(2):89-94. PubMed ID: 16402088
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenetics--pivotal to the future of the biopharmaceutical industry.
    Foot E; Kleyn D; Palmer Foster E
    Drug Discov Today; 2010 May; 15(9-10):325-7. PubMed ID: 20298799
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
    Kirchheiner J; Fuhr U; Brockmöller J
    Nat Rev Drug Discov; 2005 Aug; 4(8):639-47. PubMed ID: 16056390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enabling pharmacogenomic clinical trials through sampling.
    Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
    Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.